Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction

被引:2
|
作者
Asakura, Koko [1 ,2 ]
Evans, Scott R. [3 ,4 ]
Hamasaki, Toshimitsu [2 ,3 ,4 ]
机构
[1] Natl Cerebral & Cardiovasc Ctr, Dept Data Sci, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Innovat Clin Trials & Data Sci, Osaka, Japan
[3] George Washington Univ, Biostat Ctr, 6110 Execut Blvd, Rockville, MD 20852 USA
[4] George Washington Univ, Dept Biostat & Bioinformat, 6110 Execut Blvd, Rockville, MD 20852 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2020年 / 12卷 / 02期
关键词
Conditional power; Group-sequential designs; Interim analyses; Predicted intervals; Predictive power; Type I error; SAMPLE-SIZE DETERMINATION; TERMINATION; EFFICACY;
D O I
10.1080/19466315.2019.1677494
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We discuss using prediction as a flexible and practical approach for monitoring futility in clinical trials with two co-primary endpoints (CPE). This approach is appealing in that it provides quantitative evaluation of potential effect sizes and associated precision, and can be combined with flexible error-spending strategies. We extend prediction of effect size estimates and the construction of predicted intervals to the two CPE case, and illustrate interim futility monitoring of treatment effects using prediction with an example. We also discuss alternative approaches based on the conditional and predictive powers, compare these methods and provide some guidance on the use of prediction for better decision in clinical trials with CPE.
引用
收藏
页码:164 / 175
页数:12
相关论文
共 48 条
  • [21] Sequential designs for monitoring two endpoints in a clinical trial
    Todd, S
    DRUG INFORMATION JOURNAL, 1999, 33 (02): : 417 - 426
  • [22] Sequential Designs for Monitoring Two Endpoints in a Clinical Trial
    Susan Todd
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (2): : 417 - 426
  • [23] Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution
    Waleed, Muhammad
    He, Jianghua
    Phadnis, Milind A.
    PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 610 - 644
  • [24] Monitoring Phase II Comparative Clinical Trials with Two Endpoints and Penalty for Adverse Events
    Bersimis, Sotiris
    Sachlas, Athanasios
    Papaioannou, Takis
    METHODOLOGY AND COMPUTING IN APPLIED PROBABILITY, 2018, 20 (02) : 719 - 738
  • [25] Reducing unnecessary measurements in clinical trials with multiple primary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (04) : 631 - 643
  • [26] Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
    Zocholl, Dario
    Kunz, Cornelia U.
    Rauch, Geraldine
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (09) : 1749 - 1765
  • [27] Comparison of futility monitoring guidelines using completed phase III oncology trials
    Zhang, Qiang
    Freidlin, Boris
    Korn, Edward L.
    Halabi, Susan
    Mandrekar, Sumithra
    Dignam, James J.
    CLINICAL TRIALS, 2017, 14 (01) : 48 - 58
  • [28] Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint
    Quan, Hui
    Xu, Yuqing
    Liu, Ying
    Chen, Xun
    CONTEMPORARY CLINICAL TRIALS, 2024, 138
  • [29] Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes
    Zhou, Ming
    Tang, Qi
    Lang, Lixin
    Xing, Jun
    Tatsuoka, Kay
    STATISTICS IN MEDICINE, 2018, 37 (14) : 2187 - 2207
  • [30] Selection of study endpoints and patients for clinical trials in primary Sjogren's syndrome
    Arends, S.
    de Wolff, L.
    Deroo, L.
    Verstappen, G. M.
    Vissink, A.
    Kroese, F. G. M.
    Elewaut, D.
    Peene, I.
    Bootsma, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 2225 - 2232